Sangamo Therapeutics (SGMOQ) Income from Non-Controlling Interests (2018 - 2021)
Sangamo Therapeutics (SGMOQ) posted quarterly Income from Non-Controlling Interests of -$5000.0 for Q2 2021, up 86.11% year-over-year from -$2686.6 in Q2 2020, and up 16.67% quarter-over-quarter from -$6000.0 in Q1 2021.
Sangamo Therapeutics (SGMOQ) Income from Non-Controlling Interests (2018 - 2021) Analysis & Trends
Sangamo Therapeutics' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at -$5000.0 for Q2 2021.
- In Q2 2021, Income from Non-Controlling Interests rose 86.11% year-over-year to -$5000.0; the TTM figure through Mar 2022 stood at -$5000.0 (up 92.96% YoY), while the FY2021 annual figure was -$11000.0, up 91.27% from the prior year.
- Income from Non-Controlling Interests for Q2 2021 stood at -$5000.0, up from -$6000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $42000.0 in Q3 2020, with the low at -$555000.0 in Q4 2018.
- The 4-year median for Income from Non-Controlling Interests is -$54000.0 (2019), against an average of -$100272.7.
- Peak annual rise in Income from Non-Controlling Interests reached 123.46% in 2020, while the deepest fall reached 31.48% in 2020.
- Sangamo Therapeutics' Income from Non-Controlling Interests stood at -$555000.0 in 2018, then jumped by 90.27% to -$54000.0 in 2019, then slumped by 31.48% to -$71000.0 in 2020, then surged by 92.96% to -$5000.0 in 2021.
- Business Quant data shows SGMOQ's Income from Non-Controlling Interests at -$5000.0 in Q2 2021, -$6000.0 in Q1 2021, and -$71000.0 in Q4 2020.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -5,000.00 |
| Mar 31, 2021 | -6,000.00 |
| Dec 31, 2020 | -71,000.00 |
| Sep 30, 2020 | 42,000.00 |
| Jun 30, 2020 | -36,000.00 |
| Mar 31, 2020 | -61,000.00 |
| Dec 31, 2019 | -54,000.00 |
| Sep 30, 2019 | -179,000.00 |
| Jun 30, 2019 | -125,000.00 |
| Mar 31, 2019 | -53,000.00 |
| Dec 31, 2018 | -555,000.00 |